{"id":24417,"date":"2022-11-11T15:07:00","date_gmt":"2022-11-11T07:07:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24417"},"modified":"2025-01-31T15:17:22","modified_gmt":"2025-01-31T07:17:22","slug":"baheal-partners-with-astrazeneca-for-commercial-rights-to-onglyza","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24417","title":{"rendered":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza"},"content":{"rendered":"\n

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN<\/a>), securing commercial operation rights to the UK major\u2019s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.<\/p>\n\n\n\n

Saxagliptin Profile<\/strong>
Saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor originally developed by Bristol-Myers Squibb (BMS, NYSE: BMY<\/a>) for the treatment of type II diabetes, was first approved in the US in 2009. The drug was later acquired by AstraZeneca and obtained marketing approval in China in 2011. In 2017, Onglyza and four other DPP4 inhibitors were included on China’s National Reimbursement Drug List (NRDL), further expanding its market reach.<\/p>\n\n\n\n

Market Landscape and Generic Competition<\/strong>
In January 2019, Aosaikang Pharma\u2019s generic version of saxagliptin was approved in China, followed by versions manufactured by Chi Tai Tianqing, Hansoh Pharma, Qilu Pharma, Winsunny Harmony, and Cosource Pharma. Notably, saxagliptin was included in the fifth volume-based procurement (VBP) round held in June 2021, with Hansoh, Chi Tai, Aosaikang, and Qilu Pharma winning tender spots for the drug. This inclusion highlights the drug’s significance in the Chinese market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[130,770,429,428,871,849],"class_list":["post-24417","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astrazeneca","tag-az","tag-bms","tag-bristol-myers-squibb","tag-nasdaq-azn","tag-nyse-bmy"],"yoast_head":"\nBaheal Partners with AstraZeneca for Commercial Rights to Onglyza - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN), securing commercial operation rights to the UK major\u2019s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24417\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24417\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-11T07:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T07:17:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza\",\"datePublished\":\"2022-11-11T07:07:00+00:00\",\"dateModified\":\"2025-01-31T07:17:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"BMS\",\"Bristol-Myers Squibb\",\"NASDAQ: AZN\",\"NYSE: BMY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24417#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24417\",\"name\":\"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-11T07:07:00+00:00\",\"dateModified\":\"2025-01-31T07:17:22+00:00\",\"description\":\"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN), securing commercial operation rights to the UK major\u2019s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24417\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24417#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza - Insight, China's Pharmaceutical Industry","description":"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN), securing commercial operation rights to the UK major\u2019s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24417","og_locale":"en_US","og_type":"article","og_title":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24417","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-11T07:07:00+00:00","article_modified_time":"2025-01-31T07:17:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24417#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24417"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza","datePublished":"2022-11-11T07:07:00+00:00","dateModified":"2025-01-31T07:17:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24417"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","BMS","Bristol-Myers Squibb","NASDAQ: AZN","NYSE: BMY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24417#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24417","url":"https:\/\/flcube.com\/?p=24417","name":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-11T07:07:00+00:00","dateModified":"2025-01-31T07:17:22+00:00","description":"China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN), securing commercial operation rights to the UK major\u2019s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24417#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24417"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24417#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Baheal Partners with AstraZeneca for Commercial Rights to Onglyza"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24417"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24417\/revisions"}],"predecessor-version":[{"id":24418,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24417\/revisions\/24418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}